99-20381. Proposed Data Collections Submitted for Public Comment and Recommendations

[Federal Register Volume 64, Number 152 (Monday, August 9, 1999)]
[Notices]
[Pages 43187-43188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-20381]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[INFO-99-25]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on [phone].
    Comments are invited on (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques for other 
forms of information technology. Send comments to Seleda Perryman, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.

Proposed Projects

    1. Antimalarial Drugs--New--The Division of Parasitic Diseases, 
National Center for Infectious Diseases, Centers for Disease Control 
and Prevention (CDC), is proposing a survey of pharmacy directors of 
inpatient health facilities to gain information about the availability 
of antimalarial medications in their pharmacies. In recent years, CDC 
has received increasing numbers of reports from health care providers 
and patients who have been unable to obtain, or experienced delays in 
obtaining, antimalarial drugs which were needed for patients in the 
United States who have been diagnosed with malaria. In the case of 
injectable quinidine gluconate, which is the treatment of choice for 
severe malaria, these delays in initiating appropriate therapy have 
been life threatening. The reasons for these shortages have varied from 
problems in drug supply and distribution from the manufacturer to 
decisions made by pharmacies to no longer stock the drugs. The American 
Society of Health System Pharmacists (ASHP) will provide CDC with a 
list of approximately 7,400 pharmacy directors of inpatient 
institutions in the U.S. Those listed will be surveyed through a mailed 
questionnaire. Participation in completing the proposed questionnaire 
will be voluntary. Information collected will include the pharmacy name 
and location, name of the pharmacy director, number of inpatient beds 
in the health facility, a list of antimalarial medications currently on 
formulary and in stock, the procedure and anticipated delay in 
obtaining injectable quinidine if needed and not currently in stock, 
and, if quinidine is no longer on formulary, the date it was taken off. 
Such information is essential for CDC to determine the potential need 
for and various options to improve the availability of critical 
antimalarial drugs in the United States. The total estimated cost to 
respondents is 0.

----------------------------------------------------------------------------------------------------------------
                                                                  Number of      Average burden  Response burden
                    Form                         Number of      responses per   per  respondent   (total hrs. in
                                                respondents       respondent       (in hrs.)          study)
----------------------------------------------------------------------------------------------------------------
Questionnaire...............................           7,400                1             0.16             1184
----------------------------------------------------------------------------------------------------------------


[[Page 43188]]

Nancy Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 99-20381 Filed 8-6-99; 8:45 am]
BILLING CODE 4163-18-P